NCT06608511

Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 20 (estimated)
• Sponsor: University of Wisconsin, Madison · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this observational study is to study blood samples and compare them to other biospecimens and clinical outcomes in participants who have melanoma or non-melanoma skin cancers. The main question it aims to answer is: * Are blood based signatures able to predict progression-free survival (PFS)? Participants undergoing regular treatment for their skin cancer will provide blood samples.

Detailed description

This observational study is being done to identify possible biomarkers that can be used for prognostic, prediction, or monitoring considerations in patients with melanoma or non-melanoma skin cancer undergoing treatment. Investigators plan to investigate blood factors which include circulating tumor cells (CTCs - i.e., cancer cells that can be detected in the blood) and their associated protein and mRNA expression; circulating tumor DNA (ctDNA - i.e., pieces of DNA from cancer cells that can be found in the blood); and tumor-derived exosomes (i.e., extracellular vesicles generated by cancer cells that carry nucleic acids, proteins, and metabolites).

Conditions

• Skin Cancer
• Melanoma (Skin Cancer)
• Basal Cell Carcinoma of Skin
• Basal Cell Carcinoma of Skin, Site Unspecified
• Cutaneous Squamous Cell Carcinoma (CSCC)
• Merkel Cell Carcinoma of Skin

Interventions

Type	Name	Description
OTHER	Blood draw for the laboratory assessment	Participants will have 50 milliliters (3.5 tablespoons) of blood drawn

Timeline

• Start date: 2024-12-11
• Primary completion: 2026-12-01
• Completion: 2026-12-01
• First posted: 2024-09-23
• Last updated: 2025-12-17

Locations

1 site across 1 country: United States